Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm phase 4 study of inebilizumab in adults with AQP4-IgG-positive NMOSD
CTR20234069Phase 4Active
- Sponsor
- Viela Bio
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Viela Bio. Started Mar 2024; status: active.
02
Drugs
inebilizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on CTR20234069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234069.